We used classical molecular mechanics (MM) simulations and quantum mechanical (QM) structural relaxations to examine the active site of myosin when bound to ATP. Two conformations of myosin have been determined by x-ray crystallography. In one, there is no direct interaction between switch 2 and the nucleotide (open state). In the other (closed state), the universally conserved switch 2 glycine forms a hydrogen bond with a gamma-phosphate oxygen. MM simulations indicate that the two states are thermodynamically stable and allow us to investigate the extent to which the P-loop, switch 1, and switch 2 are involved in hydrolysis. We find that the open structure has a higher affinity for ATP than the closed structure, and that ATP is distorted toward a transition state by interactions with the protein. We also examine how the structure of the binding site changes with either MgATP or CaATP as the nucleotide in myosin in the open conformer. Our analyses suggest that higher CaATPase rates occur because the leaving phosphate (P(i)) group is more weakly bound and dissociation occurs faster. Finally, we validate the use of a particular formulation of a QM methodology (Car-Parrinello) to further refine the structures of the active site.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1301876PMC
http://dx.doi.org/10.1016/S0006-3495(02)75429-5DOI Listing

Publication Analysis

Top Keywords

active site
8
classical initio
4
initio study
4
study interaction
4
myosin
4
interaction myosin
4
myosin triphosphate
4
triphosphate binding
4
binding domain
4
atp
4

Similar Publications

ConspectusIn the search for efficient and selective electrocatalysts capable of converting greenhouse gases to value-added products, enzymes found in naturally existing bacteria provide the basis for most approaches toward electrocatalyst design. Ni,Fe-carbon monoxide dehydrogenase (Ni,Fe-CODH) is one such enzyme, with a nickel-iron-sulfur cluster named the C-cluster, where CO binds and is converted to CO at high rates near the thermodynamic potential. In this Account, we divide the enzyme's catalytic contributions into three categories based on location and function.

View Article and Find Full Text PDF

A terpene synthase gene (mtas) from Menisporopsis theobromae BCC 4162 was heterologously expressed in Aspergillus oryzae NSAR1, resulting in the production of (+)-aristolochene. Mutations were introduced in MtAS at aromatic residues (Y83, F103, F169, and W323) surrounding the active site, which are critical for precursor cyclisation and intermediate stabilisation during aristolochene biosynthesis. Transformants harbouring mutated mtas, specifically F103W, F169A and F169W, produced (2R,4S,5R,7S)-2-hydroxyaristolochene as the major product, along with aristolochene and other tentative metabolites, including germacrene A and sesquiterpenoids.

View Article and Find Full Text PDF

Freshwater ecosystems face significant threats, including pollution, habitat loss, invasive species, and climate change. To address these challenges, management strategies and restoration efforts have been broadly implemented. Across Europe, such efforts have resulted in overall improvements in freshwater biodiversity, but recovery has stalled or failed to occur in many localities, which may be partly caused by the limited dispersal capacity of many species.

View Article and Find Full Text PDF

[FeFe] hydrogenases make up a structurally diverse family of metalloenzymes that catalyze proton/dihydrogen interconversion. They can be classified into phylogenetically distinct groups denoted A-G, which differ in structure and reactivity. Prototypical Group A hydrogenases have high turnover rates and remarkable energy efficiency.

View Article and Find Full Text PDF

Angiotensin-I converting enzyme (ACE) regulates the levels of disparate bioactive peptides, notably converting angiotensin-I to angiotensin-II and degrading amyloid beta. ACE is a heavily glycosylated dimer, containing 4 analogous catalytic sites, and exists in membrane bound and soluble (sACE) forms. ACE inhibition is a frontline, FDA-approved, therapy for cardiovascular diseases yet is associated with significant side effects, including higher rates of lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!